JP2016521979A - 腎臓がんを有する患者に対する再発スコアを計算するための遺伝子発現プロファイルアルゴリズム - Google Patents

腎臓がんを有する患者に対する再発スコアを計算するための遺伝子発現プロファイルアルゴリズム Download PDF

Info

Publication number
JP2016521979A
JP2016521979A JP2016516815A JP2016516815A JP2016521979A JP 2016521979 A JP2016521979 A JP 2016521979A JP 2016516815 A JP2016516815 A JP 2016516815A JP 2016516815 A JP2016516815 A JP 2016516815A JP 2016521979 A JP2016521979 A JP 2016521979A
Authority
JP
Japan
Prior art keywords
gene
level
genes
expression
rna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016516815A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016521979A5 (cg-RX-API-DMAC7.html
Inventor
スティーブン シャク，
スティーブン シャク，
ジョージ アンドリュー ワトソン，
ジョージ アンドリュー ワトソン，
マイケル アール． クレイガー，
マイケル アール． クレイガー，
タラ マダラ，
タラ マダラ，
マルガリータ ロパーチン，
マルガリータ ロパーチン，
オードリー ゴダード，
オードリー ゴダード，
デジャン ネゼビック，
デジャン ネゼビック，
クリステル スベッドマン，
クリステル スベッドマン，
Original Assignee
ジェノミック ヘルス， インコーポレイテッド
ジェノミック ヘルス， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ジェノミック ヘルス， インコーポレイテッド, ジェノミック ヘルス， インコーポレイテッド filed Critical ジェノミック ヘルス， インコーポレイテッド
Publication of JP2016521979A publication Critical patent/JP2016521979A/ja
Publication of JP2016521979A5 publication Critical patent/JP2016521979A5/ja
Pending legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/20—Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16C—COMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE
    • G16C99/00—Subject matter not provided for in other groups of this subclass
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16Z—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS, NOT OTHERWISE PROVIDED FOR
    • G16Z99/00—Subject matter not provided for in other main groups of this subclass
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Medical Informatics (AREA)
  • Organic Chemistry (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Theoretical Computer Science (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Wood Science & Technology (AREA)
  • Evolutionary Biology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Data Mining & Analysis (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Databases & Information Systems (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Primary Health Care (AREA)
  • Computing Systems (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP2016516815A 2013-05-30 2014-05-29 腎臓がんを有する患者に対する再発スコアを計算するための遺伝子発現プロファイルアルゴリズム Pending JP2016521979A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361829100P 2013-05-30 2013-05-30
US61/829,100 2013-05-30
PCT/US2014/040003 WO2014194078A1 (en) 2013-05-30 2014-05-29 Gene expression profile algorithm for calculating a recurrence score for a patient with kidney cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018134242A Division JP2018161151A (ja) 2013-05-30 2018-07-17 腎臓がんを有する患者に対する再発スコアを計算するための遺伝子発現プロファイルアルゴリズム

Publications (2)

Publication Number Publication Date
JP2016521979A true JP2016521979A (ja) 2016-07-28
JP2016521979A5 JP2016521979A5 (cg-RX-API-DMAC7.html) 2017-04-27

Family

ID=51989393

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2016516815A Pending JP2016521979A (ja) 2013-05-30 2014-05-29 腎臓がんを有する患者に対する再発スコアを計算するための遺伝子発現プロファイルアルゴリズム
JP2018134242A Pending JP2018161151A (ja) 2013-05-30 2018-07-17 腎臓がんを有する患者に対する再発スコアを計算するための遺伝子発現プロファイルアルゴリズム
JP2020138078A Active JP7301798B2 (ja) 2013-05-30 2020-08-18 腎臓がんを有する患者に対する再発スコアを計算するための遺伝子発現プロファイルアルゴリズム

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2018134242A Pending JP2018161151A (ja) 2013-05-30 2018-07-17 腎臓がんを有する患者に対する再発スコアを計算するための遺伝子発現プロファイルアルゴリズム
JP2020138078A Active JP7301798B2 (ja) 2013-05-30 2020-08-18 腎臓がんを有する患者に対する再発スコアを計算するための遺伝子発現プロファイルアルゴリズム

Country Status (11)

Country Link
US (3) US10181008B2 (cg-RX-API-DMAC7.html)
EP (2) EP3825420A1 (cg-RX-API-DMAC7.html)
JP (3) JP2016521979A (cg-RX-API-DMAC7.html)
AU (2) AU2014274135B2 (cg-RX-API-DMAC7.html)
CA (2) CA2903878C (cg-RX-API-DMAC7.html)
DK (1) DK3004392T3 (cg-RX-API-DMAC7.html)
ES (1) ES2829415T3 (cg-RX-API-DMAC7.html)
IL (2) IL240919B (cg-RX-API-DMAC7.html)
MX (2) MX369911B (cg-RX-API-DMAC7.html)
SG (2) SG11201506987VA (cg-RX-API-DMAC7.html)
WO (1) WO2014194078A1 (cg-RX-API-DMAC7.html)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20200073305A (ko) * 2018-12-13 2020-06-24 연세대학교 산학협력단 신장 세포 암의 종양의 병리학적 등급에 대한 정보를 제공하기 위한 방법 및 장치
JP2024124408A (ja) * 2020-10-01 2024-09-12 コーニンクレッカ フィリップス エヌ ヴェ 膀胱がん又は腎臓がん対象者の転帰の予測

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018187767A1 (en) * 2017-04-06 2018-10-11 The Regents Of The University Of California Predicting, diagnosing, and treating nausea and vomiting of pregnancy
WO2019075251A2 (en) * 2017-10-12 2019-04-18 Nantomics, Llc CANCER SCORE FOR EVALUATION AND PREDICTION OF RESPONSE FROM BIOLOGICAL FLUIDS
EP3874274B1 (en) 2018-10-31 2024-01-03 Regents of the University of Minnesota Methods for predicting a response to bevacizumab or platinum-based chemotherapy or both in patients with ovarian cancer
CA3126455A1 (en) * 2019-01-11 2020-07-16 Quadrus Medical Technologies, Inc. Systems and methods for assessing and evaluating renal health diagnosis, staging, and therapy recommendation
CN113593640B (zh) * 2021-08-03 2023-07-28 哈尔滨市米杰生物科技有限公司 一种鳞癌组织功能状态与细胞组分评估方法及系统
WO2025085824A1 (en) * 2023-10-20 2025-04-24 Memorial Sloan-Kettering Cancer Center Multi-scale analysis of ribonucleic acid sequence data for predicting responses to anti-cancer therapies
CN117935910B (zh) * 2024-01-26 2024-09-17 华中农业大学 玉米snp位点的筛选方法、装置、电子设备及介质

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002079411A2 (en) * 2001-03-29 2002-10-10 Van Andel Institute Microarray gene expression profiling in clear cell renal cell carcinoma: prognosis and drug target identification
JP2007527220A (ja) * 2003-07-10 2007-09-27 ジェノミック ヘルス， インコーポレイテッド 癌診断のための発現プロフィールアルゴリズムおよび試験
JP2007528737A (ja) * 2004-05-04 2007-10-18 バイエル ヘルスケア Ｍｎ／ｃａｉｘ／ｃａ９及び腎臓癌の予後診断
JP2007532113A (ja) * 2004-04-09 2007-11-15 ジェノミック ヘルス， インコーポレイテッド 化学療法剤に対する応答を予測するための遺伝子発現マーカー
WO2013028807A2 (en) * 2011-08-22 2013-02-28 Somalogic, Inc. Renal cell carcinoma biomarkers and uses thereof
JP2013514058A (ja) * 2009-11-23 2013-04-25 ジェノミック ヘルス， インコーポレイテッド 癌の臨床転帰を予測する方法
JP2013516195A (ja) * 2010-01-11 2013-05-13 ジェノミック ヘルス， インコーポレイテッド 遺伝子発現を用いて腎癌の臨床的結果の見込みを判定する方法

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7135314B1 (en) 1997-04-17 2006-11-14 Cell Therapeutics, Inc. Human phosphatidic acid phosphatase
WO2001051635A2 (en) 2000-01-13 2001-07-19 Genentech, Inc. Novel stra6 polypeptides
US6475855B1 (en) 2000-03-01 2002-11-05 Micron Technology, Inc. Method of forming integrated circuitry, method of forming a capacitor and method of forming DRAM integrated circuitry
DE10126344A1 (de) 2000-07-14 2002-01-24 Max Planck Gesellschaft Apoptose-induzierende DNA-Sequenzen
WO2002027028A1 (en) 2000-09-28 2002-04-04 Atairgin Technologies, Inc. A method of determining tumor characteristics by determining abnormal copy number or expression level of lipid-associated genes
US20030109434A1 (en) 2001-03-19 2003-06-12 Corixa Corporation Compositions and methods for the therapy and diagnosis of kidney cancer
JP2005500832A (ja) 2001-06-18 2005-01-13 ロゼッタ・インファーマティクス・インコーポレーテッド 乳癌患者の診断および予後
US7470509B2 (en) 2002-02-08 2008-12-30 Millennium Pharmaceuticals, Inc. Compositions and methods for the identification, assessment, prevention and therapy of ovarian cancer
DK1918386T3 (da) 2002-03-13 2012-01-02 Genomic Health Inc Genekspressionsprofiler i biopsier af tumorvæv
WO2004032842A2 (en) 2002-10-04 2004-04-22 Van Andel Research Institute Molecular sub-classification of kidney tumors and the discovery of new diagnostic markers
US7611839B2 (en) 2002-11-21 2009-11-03 Wyeth Methods for diagnosing RCC and other solid tumors
CA2523798A1 (en) 2003-04-29 2004-11-11 Wyeth Methods for prognosis and treatment of solid tumors
CA2530738C (en) 2003-06-24 2020-01-21 Genomic Health, Inc. Prediction of likelihood of cancer recurrence
WO2005005661A2 (en) 2003-07-02 2005-01-20 Novartis Ag Genes regulated in ovarian cancer as prognostic and therapeutic targets
US20050002904A1 (en) 2003-07-03 2005-01-06 Wary Kishore K. Uses of vascular endothelial growth factor and type I collagen inducible protein (VCIP)
JP2005211023A (ja) 2004-01-30 2005-08-11 Hayashibara Biochem Lab Inc 腎細胞癌の転移若しくは再発の可能性を予測する方法
US20070224596A1 (en) 2004-04-09 2007-09-27 Mariana Nacht Compositions and methods for the modifying hypoxia induced gene regulation
CN101023185A (zh) 2004-05-27 2007-08-22 威特克斯医药股份有限公司 用于监测impdh通路抑制作用的生物学标记
US7587279B2 (en) 2004-07-06 2009-09-08 Genomic Health Method for quantitative PCR data analysis system (QDAS)
US20080119367A1 (en) 2004-12-17 2008-05-22 Mayo Foundation For Medical Education And Research Prognosis of Renal Cell Carcinoma
US20090258002A1 (en) 2005-02-01 2009-10-15 Government Of The Us, As Represented By The Secretary, Department Of Health And Human Services Biomarkers for Tissue Status
US20090061423A1 (en) 2005-02-18 2009-03-05 Wyeth Pharmacogenomic markers for prognosis of solid tumors
WO2006124836A1 (en) 2005-05-13 2006-11-23 Duke University Gene expression signatures for oncogenic pathway deregulation
WO2006124022A1 (en) 2005-05-13 2006-11-23 Vanandel Research Institute Microarray gene expression profiling in subtypes of clear cell renal cell carcinoma
US20070037186A1 (en) 2005-05-20 2007-02-15 Yuqiu Jiang Thyroid fine needle aspiration molecular assay
EP1899486A4 (en) 2005-06-08 2009-07-22 Millennium Pharm Inc METHOD FOR IDENTIFYING, ASSESSING AND TREATING PATIENTS IN CANCER THERAPY
WO2006138275A2 (en) 2005-06-13 2006-12-28 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
WO2006135886A2 (en) 2005-06-13 2006-12-21 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
JP4312256B2 (ja) 2005-06-15 2009-08-12 ファイザー・リミテッド 寄生生物に対して使用する置換アリールピラゾール
EP1930426A4 (en) 2005-09-02 2009-04-29 Toray Industries COMPOSITION AND METHOD FOR DIAGNOSING KIDNEY CANCER AND ASSESSING THE PROGNOSIS OF A KIDNEY CANCER PATIENTS
US8343738B2 (en) 2005-09-14 2013-01-01 Human Genetic Signatures Pty. Ltd. Assay for screening for potential cervical cancer
EP2332984A3 (en) 2005-09-30 2011-10-12 Universiteit Maastricht Tumor angiogenesis associated genes and a method for their identification
EP1777523A1 (en) 2005-10-19 2007-04-25 INSERM (Institut National de la Santé et de la Recherche Médicale) An in vitro method for the prognosis of progression of a cancer and of the outcome in a patient and means for performing said method
US8445198B2 (en) 2005-12-01 2013-05-21 Medical Prognosis Institute Methods, kits and devices for identifying biomarkers of treatment response and use thereof to predict treatment efficacy
EP1960551A2 (en) 2005-12-01 2008-08-27 Medical Prognosis Institute Methods and devices for identifying biomarkers of treatment response and use thereof to predict treatment efficacy
WO2007111733A2 (en) 2005-12-16 2007-10-04 Genentech, Inc. Method for diagnosing, prognosing and treating glioma
US20080242606A1 (en) 2006-06-06 2008-10-02 Zhong Jiang Use of IMP3 as a Prognostic Marker for Cancer
MX2009001489A (es) 2006-08-10 2009-02-18 Millennium Pharm Inc Para la identificacion, valoracion y tratamiento de pacientes con terapia de cancer.
US8450057B2 (en) 2006-08-14 2013-05-28 The Brigham And Women's Hospital, Inc. Diagnostic tests using gene expression ratios
US9034574B2 (en) * 2006-12-27 2015-05-19 The Johns Hopkins University Agents for reversing epigenetic silencing of genes
US20080286273A1 (en) 2007-05-02 2008-11-20 Siemens Medical Solutions Usa, Inc. Knowledge-Based Proliferation Signatures and Methods of Use
EP1990417A1 (en) 2007-05-11 2008-11-12 Universität Bayreuth Archaeal plasmid vector system
WO2009105640A1 (en) 2008-02-22 2009-08-27 Virginia Commonwealth University Signatures associated with rejection or recurrence of cancer
CA2743473C (en) 2008-11-17 2022-06-14 Veracyte, Inc. Methods and compositions of molecular profiling for disease diagnostics
AU2010264763B2 (en) 2009-06-26 2015-07-23 Noviogendix Research B.V. Molecular markers in kidney cancer
US9005891B2 (en) 2009-11-10 2015-04-14 Genomic Health, Inc. Methods for depleting RNA from nucleic acid samples
WO2012174282A2 (en) * 2011-06-16 2012-12-20 Caris Life Sciences Luxembourg Holdings, S.A.R.L. Biomarker compositions and methods

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002079411A2 (en) * 2001-03-29 2002-10-10 Van Andel Institute Microarray gene expression profiling in clear cell renal cell carcinoma: prognosis and drug target identification
JP2007527220A (ja) * 2003-07-10 2007-09-27 ジェノミック ヘルス， インコーポレイテッド 癌診断のための発現プロフィールアルゴリズムおよび試験
JP2007532113A (ja) * 2004-04-09 2007-11-15 ジェノミック ヘルス， インコーポレイテッド 化学療法剤に対する応答を予測するための遺伝子発現マーカー
JP2007528737A (ja) * 2004-05-04 2007-10-18 バイエル ヘルスケア Ｍｎ／ｃａｉｘ／ｃａ９及び腎臓癌の予後診断
JP2013514058A (ja) * 2009-11-23 2013-04-25 ジェノミック ヘルス， インコーポレイテッド 癌の臨床転帰を予測する方法
JP2013516195A (ja) * 2010-01-11 2013-05-13 ジェノミック ヘルス， インコーポレイテッド 遺伝子発現を用いて腎癌の臨床的結果の見込みを判定する方法
WO2013028807A2 (en) * 2011-08-22 2013-02-28 Somalogic, Inc. Renal cell carcinoma biomarkers and uses thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
INT. J. CANCER, 2008, VOL.123, P.1126-1132, JPN6018013109, ISSN: 0003918760 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20200073305A (ko) * 2018-12-13 2020-06-24 연세대학교 산학협력단 신장 세포 암의 종양의 병리학적 등급에 대한 정보를 제공하기 위한 방법 및 장치
KR102280204B1 (ko) 2018-12-13 2021-07-21 연세대학교 산학협력단 신장 세포 암의 종양의 병리학적 등급에 대한 정보를 제공하기 위한 방법 및 장치
JP2024124408A (ja) * 2020-10-01 2024-09-12 コーニンクレッカ フィリップス エヌ ヴェ 膀胱がん又は腎臓がん対象者の転帰の予測
JP7729438B2 (ja) 2020-10-01 2025-08-26 コーニンクレッカ フィリップス エヌ ヴェ 膀胱がん又は腎臓がん対象者の転帰の予測

Also Published As

Publication number Publication date
AU2020204502A1 (en) 2020-07-23
NZ711680A (en) 2021-05-28
CA2903878C (en) 2020-10-27
US20190095575A1 (en) 2019-03-28
JP2018161151A (ja) 2018-10-18
IL283548A (en) 2021-07-29
MX2019013953A (es) 2020-01-30
EP3004392A1 (en) 2016-04-13
EP3004392A4 (en) 2017-01-25
HK1223132A1 (en) 2017-07-21
EP3825420A1 (en) 2021-05-26
AU2014274135A1 (en) 2015-09-24
SG10201709537PA (en) 2017-12-28
US20220044760A9 (en) 2022-02-10
CA3093128C (en) 2023-01-03
MX2015012782A (es) 2016-02-05
US10181008B2 (en) 2019-01-15
JP2020191896A (ja) 2020-12-03
WO2014194078A1 (en) 2014-12-04
EP3004392B1 (en) 2020-09-30
US20210151122A1 (en) 2021-05-20
CA2903878A1 (en) 2014-12-04
IL240919B (en) 2021-06-30
SG11201506987VA (en) 2015-10-29
AU2014274135B2 (en) 2020-04-09
DK3004392T3 (da) 2020-10-26
IL240919A0 (en) 2015-10-29
US20160048632A1 (en) 2016-02-18
US11551782B2 (en) 2023-01-10
MX369911B (es) 2019-11-26
ES2829415T3 (es) 2021-05-31
NZ752676A (en) 2021-05-28
CA3093128A1 (en) 2014-12-04
AU2020204502B2 (en) 2022-02-17
JP7301798B2 (ja) 2023-07-03

Similar Documents

Publication Publication Date Title
JP7385630B2 (ja) 遺伝子発現を用いて腎癌の臨床的結果の見込みを判定する方法
JP7042784B2 (ja) 遺伝子発現を用いた前立腺癌の予後を定量化する方法
JP7301798B2 (ja) 腎臓がんを有する患者に対する再発スコアを計算するための遺伝子発現プロファイルアルゴリズム
JP2016104014A (ja) 結腸直腸癌の再発および化学療法に対する応答の可能性における遺伝子発現プロファイルアルゴリズムおよび試験
US20110287958A1 (en) Method for Using Gene Expression to Determine Colorectal Tumor Stage
HK40052881A (en) Gene expression profile algorithm for calculating a recurrence score for a patient with kidney cancer
AU2015202116B2 (en) Method to use gene expression to determine likelihood of clinical outcome of renal cancer
HK1223132B (en) Gene expression profile algorithm for calculating a recurrence score for a patient with kidney cancer
NZ711680B2 (en) Gene expression profile algorithm for calculating a recurrence score for a patient with kidney cancer
NZ752676B2 (en) Gene expression profile algorithm for calculating a recurrence score for a patient with kidney cancer

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170321

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170321

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180418

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180717

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20181113

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190213

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20190626

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191025